

Edgar Filing: TRANSGENOMIC INC - Form 8-K

detection of mutations in the BCR-ABL gene that are associated with development of resistance to imatinib therapy in Chronic Myeloid Leukemia (CML) patients. A copy of the press release is filed herewith as Item 9.01 and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits

(99) Press Release, dated June 20, 2005, announcing that the Company is publishing a study demonstrating the ability of its WAVE System to enable detection of mutations in the BCR-ABL gene that are associated with development of resistance to imatinib therapy in Chronic Myeloid Leukemia (CML) patients.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC, INC.

By /s/ Michael Summers

Michael Summers
Chief Financial Officer

June 20, 2005

3